LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Percutaneous Endoscopic Gastrostomy Placement in Trauma Patients: Early vs Delayed Initiation of Enteral Feeding.

    Garner, Sydney M / Reparaz, Laura / Justice, Jessica / Foster, Alexandra P / Litzenberger, Stephanie / Bell, Nathaniel / Schaller, Stephanie L / Spoor, Kristen / Cull, John / Watson, Christopher M / Dunkelberger, Lindsey C

    The American surgeon

    2023  Volume 89, Issue 7, Page(s) 3336–3338

    Abstract: In critically ill trauma patients, adequate nutrition is essential for the body's healing process. Currently, there is no clinical standard for initiating feeds after percutaneous endoscopic gastrostomy (PEG) tube placement. We aimed to demonstrate that ... ...

    Abstract In critically ill trauma patients, adequate nutrition is essential for the body's healing process. Currently, there is no clinical standard for initiating feeds after percutaneous endoscopic gastrostomy (PEG) tube placement. We aimed to demonstrate that early enteral nutrition (EN) is as safe as delayed EN in patients who have undergone PEG tube insertion. We conducted a multi-center, retrospective cohort study of 384 patients from the Prisma Health Trauma Registries who received PEGs. Feeding intolerance was defined as high gastric residuals, nausea, emesis, sustained diarrhea, or ileus. The probability that a patient would experience intolerance was 11.7% in those fed within 6 hours, 5.1% among patients fed between 6 and 12 hours, 6.0% among patients fed between 12 and 24 hours, and 7.6% among patients fed after 24 hours, for which no statistically significant difference was detected. These findings support that early EN after PEG placement is safe in critically ill, trauma patients.
    MeSH term(s) Humans ; Infant, Newborn ; Enteral Nutrition ; Gastrostomy ; Retrospective Studies ; Critical Illness/therapy ; Endoscopy
    Language English
    Publishing date 2023-02-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 202465-2
    ISSN 1555-9823 ; 0003-1348
    ISSN (online) 1555-9823
    ISSN 0003-1348
    DOI 10.1177/00031348231157880
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uk I Zs.106: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

    Glitza Oliva, Isabella C / Ferguson, Sherise D / Bassett, Roland / Foster, Alexandra P / John, Ida / Hennegan, Tarin D / Rohlfs, Michelle / Richard, Jessie / Iqbal, Masood / Dett, Tina / Lacey, Carol / Jackson, Natalie / Rodgers, Theresa / Phillips, Suzanne / Duncan, Sheila / Haydu, Lauren / Lin, Ruitao / Amaria, Rodabe N / Wong, Michael K /
    Diab, Adi / Yee, Cassian / Patel, Sapna P / McQuade, Jennifer L / Fischer, Grant M / McCutcheon, Ian E / O'Brien, Barbara J / Tummala, Sudhakar / Debnam, Matthew / Guha-Thakurta, Nandita / Wargo, Jennifer A / Carapeto, Fernando C L / Hudgens, Courtney W / Huse, Jason T / Tetzlaff, Michael T / Burton, Elizabeth M / Tawbi, Hussein A / Davies, Michael A

    Nature medicine

    2024  

    Language English
    Publishing date 2024-04-22
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-024-02998-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4212: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

    Glitza Oliva, Isabella C / Ferguson, Sherise D / Bassett, Roland / Foster, Alexandra P / John, Ida / Hennegan, Tarin D / Rohlfs, Michelle / Richard, Jessie / Iqbal, Masood / Dett, Tina / Lacey, Carol / Jackson, Natalie / Rodgers, Theresa / Phillips, Suzanne / Duncan, Sheila / Haydu, Lauren / Lin, Ruitao / Amaria, Rodabe N / Wong, Michael K /
    Diab, Adi / Yee, Cassian / Patel, Sapna P / McQuade, Jennifer L / Fischer, Grant M / McCutcheon, Ian E / O'Brien, Barbara J / Tummala, Sudhakar / Debnam, Matthew / Guha-Thakurta, Nandita / Wargo, Jennifer A / Carapeto, Fernando C L / Hudgens, Courtney W / Huse, Jason T / Tetzlaff, Michael T / Burton, Elizabeth M / Tawbi, Hussein A / Davies, Michael A

    Nature medicine

    2023  Volume 29, Issue 4, Page(s) 898–905

    Abstract: There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in ... ...

    Abstract There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in patients with melanoma and LMD. The primary endpoints are determination of safety and the recommended IT nivolumab dose. The secondary endpoint is overall survival (OS). Patients are treated with IT nivolumab alone in cycle 1 and IV nivolumab is included in subsequent cycles. We treated 25 patients with metastatic melanoma using 5, 10, 20 and 50 mg of IT nivolumab. There were no dose-limiting toxicities at any dose level. The recommended IT dose of nivolumab is 50 mg (with IV nivolumab 240 mg) every 2 weeks. Median OS was 4.9 months, with 44% and 26% OS rates at 26 and 52 weeks, respectively. These initial results suggest that concurrent IT and IV nivolumab is safe and feasible with potential efficacy in patients with melanoma LMD, including in patients who had previously received anti-PD1 therapy. Accrual to the study continues, including in patients with lung cancer. ClinicalTrials.gov registration: NCT03025256 .
    MeSH term(s) Humans ; Nivolumab ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Melanoma/pathology ; Lung Neoplasms/drug therapy ; Treatment Outcome ; Ipilimumab
    Chemical Substances Nivolumab (31YO63LBSN) ; Ipilimumab
    Language English
    Publishing date 2023-03-30
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-022-02170-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4212: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top